Historical Valuation
Aytu Biopharma Inc (AYTU) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.48 is considered Undervalued compared with the five-year average of -1.86. The fair price of Aytu Biopharma Inc (AYTU) is between 6.07 to 7.15 according to relative valuation methord. Compared to the current price of 2.65 USD , Aytu Biopharma Inc is Undervalued By 56.33%.
Relative Value
Fair Zone
6.07-7.15
Current Price：2.65
56.33%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Aytu Biopharma Inc (AYTU) has a current Price-to-Book (P/B) ratio of 1.18. Compared to its 3-year average P/B ratio of 0.45 , the current P/B ratio is approximately 163.01% higher. Relative to its 5-year average P/B ratio of 0.51, the current P/B ratio is about 134.26% higher. Aytu Biopharma Inc (AYTU) has a Forward Free Cash Flow (FCF) yield of approximately -5.16%. Compared to its 3-year average FCF yield of -47.39%, the current FCF yield is approximately -89.11% lower. Relative to its 5-year average FCF yield of -69.38% , the current FCF yield is about -92.56% lower.
P/B
Median3y
0.45
Median5y
0.51
FCF Yield
Median3y
-47.39
Median5y
-69.38
Competitors Valuation Multiple
AI Analysis for AYTU
The average P/S ratio for AYTU competitors is 4.33, providing a benchmark for relative valuation. Aytu Biopharma Inc Corp (AYTU.O) exhibits a P/S ratio of 0.48, which is -88.86% above the industry average. Given its robust revenue growth of -16.21%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AYTU
1Y
3Y
5Y
Market capitalization of AYTU increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AYTU in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AYTU currently overvalued or undervalued?
Aytu Biopharma Inc (AYTU) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.48 is considered Undervalued compared with the five-year average of -1.86. The fair price of Aytu Biopharma Inc (AYTU) is between 6.07 to 7.15 according to relative valuation methord. Compared to the current price of 2.65 USD , Aytu Biopharma Inc is Undervalued By 56.33% .
What is Aytu Biopharma Inc (AYTU) fair value?
AYTU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aytu Biopharma Inc (AYTU) is between 6.07 to 7.15 according to relative valuation methord.
How does AYTU's valuation metrics compare to the industry average?
The average P/S ratio for AYTU's competitors is 4.33, providing a benchmark for relative valuation. Aytu Biopharma Inc Corp (AYTU) exhibits a P/S ratio of 0.48, which is -88.86% above the industry average. Given its robust revenue growth of -16.21%, this premium appears unsustainable.
What is the current P/B ratio for Aytu Biopharma Inc (AYTU) as of Jan 09 2026?
As of Jan 09 2026, Aytu Biopharma Inc (AYTU) has a P/B ratio of 1.18. This indicates that the market values AYTU at 1.18 times its book value.
What is the current FCF Yield for Aytu Biopharma Inc (AYTU) as of Jan 09 2026?
As of Jan 09 2026, Aytu Biopharma Inc (AYTU) has a FCF Yield of -5.16%. This means that for every dollar of Aytu Biopharma Inc’s market capitalization, the company generates -5.16 cents in free cash flow.
What is the current Forward P/E ratio for Aytu Biopharma Inc (AYTU) as of Jan 09 2026?
As of Jan 09 2026, Aytu Biopharma Inc (AYTU) has a Forward P/E ratio of -3.00. This means the market is willing to pay $-3.00 for every dollar of Aytu Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aytu Biopharma Inc (AYTU) as of Jan 09 2026?
As of Jan 09 2026, Aytu Biopharma Inc (AYTU) has a Forward P/S ratio of 0.48. This means the market is valuing AYTU at $0.48 for every dollar of expected revenue over the next 12 months.